BTO vs NXP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard shows a Piotroski F-Score of 5/9, indicating stable financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. BTO trades at a significant discount to the Graham Number ($77.36) with a current price of $36.94, suggesting deep value characteristics, yet the extremely high forward P/E of 307.83 raises sustainability concerns. Strong profitability metrics like a 593.63% profit margin and 25.45% ROE are offset by weak technical trends (10/100) and liquidity risks from a 0.08 current ratio. The 6.96% dividend yield with a low 32.7% payout ratio supports income appeal, but lack of analyst coverage and insider enthusiasm (40/100) limits conviction.
NXP exhibits severe valuation misalignment, trading at $14.16 despite a Graham Number of $6.95 and an Intrinsic Value of $1.05. While the Piotroski F-Score of 5/9 indicates stable financial health, this is overshadowed by a catastrophic payout ratio of 418%, signaling an unsustainable dividend. Negative earnings growth (-11.2% YoY) combined with an astronomical P/E ratio of 94.40 suggests the asset is significantly overpriced relative to its fundamental earning power. The technical trend is completely bearish (0/100), reinforcing a negative outlook.
Compare Another Pair
Related Comparisons
BTO vs NXP: Head-to-Head Comparison
This page compares John Hancock Financial Opportunities Fund (BTO) and Nuveen Select Tax-Free Income Portfolio (NXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.